<!DOCTYPE html><html lang="en-us" >


<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  
  
  
    <meta name="generator" content="Wowchemy 5.6.0 for Hugo" />
  

  
  












  
  










  







  
  
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  

  
  
  
    
      
      <link rel="preload" as="style" href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap">
      <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap" media="print" onload="this.media='all'">
    
  

  
  
  
  
  
    
    
    
  
  

  <meta name="author" content="Vlad Popovici" />

  
  
  
    
  
  <meta name="description" content="Biomarker-guided treatment for patients with colon cancer is needed. We tested ABCG2 and topoisomerase 1 (TOP1) mRNA expression as predictive biomarkers for irinotecan benefit in the PETACC-3 patient cohort. The present study included 580 patients with mRNA expression data from Stage III colon cancer samples from the PETACC-3 study, which randomized the patients to Fluorouracil/leucovorin (5FUL) &#43;/− irinotecan. The primary end-points were recurrence free survival (RFS) and overall survival (OS). Patients were divided into one group with high ABCG2 expression (above median) and low TOP-1 expression (below 75 percentile) (“resistant”) (n = 216) and another group including all other combinations of these two genes (“sensitive”) (n = 364). The rationale for the cut-offs were based on the distribution of expression levels in the PETACC-3 Stage II set of patients, where ABCG2 was unimodal and TOP1 was bimodal with a high expression level mode in the top quarter of the patients. Cox proportional hazards regression was used to estimate the hazard ratios and the association between variables and end-points and log-rank tests to assess the statistical significance of differences in survival between groups. Kaplan-Meier estimates of the survival functions were used for visualization and estimation of survival rates at specific time points. Significant differences were found for both RFS (Hazard ratio (HR): 0.63 (0.44–0.92); p = 0.016) and OS (HR: 0.60 (0.39–0.93); p = 0.02) between the two biomarker groups when the patients received FOLFIRI (5FUL&#43;irinotecan). Considering only the Microsatellite Stable (MSS) and Microsatellite Instability-Low (MSI-L) patients (n = 470), the differences were even more pronounced. In contrast, no significant differences were observed between the groups when patients received 5FUL alone. This study shows that the combination of ABCG2 and TOP1 gene expression significantly divided the Stage III colon cancer patients into two groups regarding benefit from adjuvant treatment with FOLFIRI but not 5FUL." />

  
  <link rel="alternate" hreflang="en-us" href="https://bioinfo-recetox.github.io/publication/2020-cancers/" />

  
  
  
    <meta name="theme-color" content="#3f51b5" />
  

  
  

  

  <link rel="stylesheet" href="/css/vendor-bundle.min.c7b8d9abd591ba2253ea42747e3ac3f5.css" media="print" onload="this.media='all'">

  
  
  
    
    
      <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/academicons@1.9.1/css/academicons.min.css" integrity="sha512-W0xM4mr6dEP9nREo7Z9z+9X70wytKvMGeDsj7ps2+xg5QPrEBXC8tAW1IFnzjR6eoJ90JmCnFzerQJTLzIEHjA==" crossorigin="anonymous" media="print" onload="this.media='all'">
    

    
    
    
    
      
      
    
    
    

    
    
    
      <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/leaflet@1.7.1/dist/leaflet.min.css" integrity="" crossorigin="anonymous" media="print" onload="this.media='all'">
    

    

    
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      
        
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
  

  
  
  
  
  
  
  <link rel="stylesheet" href="/css/wowchemy.47f3fb8fc1366a63625e60f327964c02.css" />

  
  
  
  
  
  
  
    
    
    <link rel="stylesheet" href="/css/libs/chroma/github-light.min.css" title="hl-light" media="print" onload="this.media='all'" >
    <link rel="stylesheet" href="/css/libs/chroma/dracula.min.css" title="hl-dark" media="print" onload="this.media='all'" disabled>
  

  
  



  


  


  




  
  
  

  
  

  
  
    <link rel="manifest" href="/manifest.webmanifest" />
  

  
  <link rel="icon" type="image/png" href="/media/icon_hub5cd333a9ad2ed2c4484e85fbbb63248_94796_32x32_fill_lanczos_center_3.png" />
  <link rel="apple-touch-icon" type="image/png" href="/media/icon_hub5cd333a9ad2ed2c4484e85fbbb63248_94796_180x180_fill_lanczos_center_3.png" />

  <link rel="canonical" href="https://bioinfo-recetox.github.io/publication/2020-cancers/" />

  
  
  
  
  
  
  
  
    
  
  

  
  
    
    
  
  <meta property="twitter:card" content="summary_large_image" />
  
  <meta property="og:site_name" content="IB2: Integrative Bioinformatics and Biostatistics" />
  <meta property="og:url" content="https://bioinfo-recetox.github.io/publication/2020-cancers/" />
  <meta property="og:title" content="An explorative analysis of ABCG2/TOP-1 mRNA expression as a biomarker test for FOLFIRI treatment in stage III colon cancer patients: results from retrospective analyses of the PETACC-3 trial | IB2: Integrative Bioinformatics and Biostatistics" />
  <meta property="og:description" content="Biomarker-guided treatment for patients with colon cancer is needed. We tested ABCG2 and topoisomerase 1 (TOP1) mRNA expression as predictive biomarkers for irinotecan benefit in the PETACC-3 patient cohort. The present study included 580 patients with mRNA expression data from Stage III colon cancer samples from the PETACC-3 study, which randomized the patients to Fluorouracil/leucovorin (5FUL) &#43;/− irinotecan. The primary end-points were recurrence free survival (RFS) and overall survival (OS). Patients were divided into one group with high ABCG2 expression (above median) and low TOP-1 expression (below 75 percentile) (“resistant”) (n = 216) and another group including all other combinations of these two genes (“sensitive”) (n = 364). The rationale for the cut-offs were based on the distribution of expression levels in the PETACC-3 Stage II set of patients, where ABCG2 was unimodal and TOP1 was bimodal with a high expression level mode in the top quarter of the patients. Cox proportional hazards regression was used to estimate the hazard ratios and the association between variables and end-points and log-rank tests to assess the statistical significance of differences in survival between groups. Kaplan-Meier estimates of the survival functions were used for visualization and estimation of survival rates at specific time points. Significant differences were found for both RFS (Hazard ratio (HR): 0.63 (0.44–0.92); p = 0.016) and OS (HR: 0.60 (0.39–0.93); p = 0.02) between the two biomarker groups when the patients received FOLFIRI (5FUL&#43;irinotecan). Considering only the Microsatellite Stable (MSS) and Microsatellite Instability-Low (MSI-L) patients (n = 470), the differences were even more pronounced. In contrast, no significant differences were observed between the groups when patients received 5FUL alone. This study shows that the combination of ABCG2 and TOP1 gene expression significantly divided the Stage III colon cancer patients into two groups regarding benefit from adjuvant treatment with FOLFIRI but not 5FUL." /><meta property="og:image" content="https://bioinfo-recetox.github.io/publication/2020-cancers/featured.png" />
    <meta property="twitter:image" content="https://bioinfo-recetox.github.io/publication/2020-cancers/featured.png" /><meta property="og:locale" content="en-us" />
  
    
      <meta
        property="article:published_time"
        content="2020-04-15T00:00:00&#43;00:00"
      />
    
    <meta property="article:modified_time" content="2020-04-15T00:00:00&#43;00:00">
  

  


    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://bioinfo-recetox.github.io/publication/2020-cancers/"
  },
  "headline": "An explorative analysis of ABCG2/TOP-1 mRNA expression as a biomarker test for FOLFIRI treatment in stage III colon cancer patients: results from retrospective analyses of the PETACC-3 trial",
  
  "image": [
    "https://bioinfo-recetox.github.io/publication/2020-cancers/featured.png"
  ],
  
  "datePublished": "2020-04-15T00:00:00Z",
  "dateModified": "2020-04-15T00:00:00Z",
  
  "author": {
    "@type": "Person",
    "name": "Jan Stenvang"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "RECETOX",
    "logo": {
      "@type": "ImageObject",
      "url": "https://bioinfo-recetox.github.io/media/icon_hub5cd333a9ad2ed2c4484e85fbbb63248_94796_192x192_fill_lanczos_center_3.png"
    }
  },
  "description": "Biomarker-guided treatment for patients with colon cancer is needed. We tested ABCG2 and topoisomerase 1 (TOP1) mRNA expression as predictive biomarkers for irinotecan benefit in the PETACC-3 patient cohort. The present study included 580 patients with mRNA expression data from Stage III colon cancer samples from the PETACC-3 study, which randomized the patients to Fluorouracil/leucovorin (5FUL) +/− irinotecan. The primary end-points were recurrence free survival (RFS) and overall survival (OS). Patients were divided into one group with high ABCG2 expression (above median) and low TOP-1 expression (below 75 percentile) (“resistant”) (n = 216) and another group including all other combinations of these two genes (“sensitive”) (n = 364). The rationale for the cut-offs were based on the distribution of expression levels in the PETACC-3 Stage II set of patients, where ABCG2 was unimodal and TOP1 was bimodal with a high expression level mode in the top quarter of the patients. Cox proportional hazards regression was used to estimate the hazard ratios and the association between variables and end-points and log-rank tests to assess the statistical significance of differences in survival between groups. Kaplan-Meier estimates of the survival functions were used for visualization and estimation of survival rates at specific time points. Significant differences were found for both RFS (Hazard ratio (HR): 0.63 (0.44–0.92); p = 0.016) and OS (HR: 0.60 (0.39–0.93); p = 0.02) between the two biomarker groups when the patients received FOLFIRI (5FUL+irinotecan). Considering only the Microsatellite Stable (MSS) and Microsatellite Instability-Low (MSI-L) patients (n = 470), the differences were even more pronounced. In contrast, no significant differences were observed between the groups when patients received 5FUL alone. This study shows that the combination of ABCG2 and TOP1 gene expression significantly divided the Stage III colon cancer patients into two groups regarding benefit from adjuvant treatment with FOLFIRI but not 5FUL."
}
</script>

  

  

  


  <title>An explorative analysis of ABCG2/TOP-1 mRNA expression as a biomarker test for FOLFIRI treatment in stage III colon cancer patients: results from retrospective analyses of the PETACC-3 trial | IB2: Integrative Bioinformatics and Biostatistics</title>

  
  
  
  











</head>


<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class="page-wrapper   " data-wc-page-id="281d1b0403ecc5315f244cb82c012051" >

  
  
  
  
  
  
  
  
  
  <script src="/js/wowchemy-init.min.1ee5462d74c6c0de1f8881b384ecc58d.js"></script>

  


<aside class="search-modal" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#" aria-label="Close"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search" class="form-control"
        aria-label="Search...">
        
      </div>

      
      

      

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>



  <div class="page-header">
    












<header class="header--fixed">
  <nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
    <div class="container-xl">

      
      <div class="d-none d-lg-inline-flex">
        <a class="navbar-brand" href="/">IB2: Integrative Bioinformatics and Biostatistics</a>
      </div>
      

      
      <button type="button" class="navbar-toggler" data-toggle="collapse"
              data-target="#navbar-content" aria-controls="navbar-content" aria-expanded="false" aria-label="Toggle navigation">
      <span><i class="fas fa-bars"></i></span>
      </button>
      

      
      <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
        <a class="navbar-brand" href="/">IB2: Integrative Bioinformatics and Biostatistics</a>
      </div>
      

      
      
      <div class="navbar-collapse main-menu-item collapse justify-content-end" id="navbar-content">

        
        <ul class="navbar-nav d-md-inline-flex">
          

          

          
          
          

          

          
          
          
          

          
            
              
              
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="/post"><span>News</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="/projects"><span>Projects</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="/people"><span>People</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="/downloads"><span>Downloads</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="/publication"><span>Publications</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="/contact"><span>Contact</span></a>
          </li>

          
          

        

          
        </ul>
      </div>

      <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">

        
        
          
        

        
        
        <li class="nav-item">
          <a class="nav-link js-search" href="#" aria-label="Search"><i class="fas fa-search" aria-hidden="true"></i></a>
        </li>
        

        
        
        

        
        

      </ul>

    </div>
  </nav>
</header>


  </div>

  <div class="page-body">
    
    
    

    








<div class="pub">

  





















  
  


<div class="article-container pt-3">
  <h1>An explorative analysis of ABCG2/TOP-1 mRNA expression as a biomarker test for FOLFIRI treatment in stage III colon cancer patients: results from retrospective analyses of the PETACC-3 trial</h1>

  

  


<div class="article-metadata">

  
  
  
  
  <div>
    

  <span >
      <a href="/author/jan-stenvang/">Jan Stenvang</a></span>, <span >
      <a href="/author/eva-budinska/">Eva Budinská</a></span>, <span >
      <a href="/author/eric-van-cutsem/">Eric van Cutsem</a></span>, <span >
      <a href="/author/fred-bosman/">Fred Bosman</a></span>, <span >
      <a href="/author/vlad-popovici/">Vlad Popovici</a></span>, <span >
      <a href="/author/nils-brunner/">Nils Brünner</a></span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    April 2020
  </span>
  

  

  

  
  
  
  

  
  

</div>

  




<div class="btn-links mb-3">
  
  








  
    
  



<a class="btn btn-outline-primary btn-page-header" href="https://www.mdpi.com/2072-6694/12/4/977/pdf?version=1587969377" target="_blank" rel="noopener">
  PDF
</a>



<a href="#" class="btn btn-outline-primary btn-page-header js-cite-modal"
        data-filename="/publication/2020-cancers/cite.bib">
  Cite
</a>





  
  <a class="btn btn-outline-primary btn-page-header" href="/project/azv2019_vp/">
    Project
  </a>
  









<a class="btn btn-outline-primary btn-page-header" href="https://doi.org/10.3390/cancers12040977" target="_blank" rel="noopener">
  DOI
</a>



</div>


</div>


<div class="article-header article-container featured-image-wrapper mt-4 mb-4" style="max-width: 720px; max-height: 722px;">
  <div style="position: relative">
    <img src="/publication/2020-cancers/featured_hu5b16f792d73718cd7b9db0f3e9df366e_2186798_720x2500_fit_q75_h2_lanczos_3.webp" width="720" height="722" alt="" class="featured-image">
    <span class="article-header-caption">Finding</span>
  </div>
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract">Biomarker-guided treatment for patients with colon cancer is needed. We tested ABCG2 and topoisomerase 1 (TOP1) mRNA expression as predictive biomarkers for irinotecan benefit in the PETACC-3 patient cohort. The present study included 580 patients with mRNA expression data from Stage III colon cancer samples from the PETACC-3 study, which randomized the patients to Fluorouracil/leucovorin (5FUL) +/− irinotecan. The primary end-points were recurrence free survival (RFS) and overall survival (OS). Patients were divided into one group with high ABCG2 expression (above median) and low TOP-1 expression (below 75 percentile) (“resistant”) (n = 216) and another group including all other combinations of these two genes (“sensitive”) (n = 364). The rationale for the cut-offs were based on the distribution of expression levels in the PETACC-3 Stage II set of patients, where ABCG2 was unimodal and TOP1 was bimodal with a high expression level mode in the top quarter of the patients. Cox proportional hazards regression was used to estimate the hazard ratios and the association between variables and end-points and log-rank tests to assess the statistical significance of differences in survival between groups. Kaplan-Meier estimates of the survival functions were used for visualization and estimation of survival rates at specific time points. Significant differences were found for both RFS (Hazard ratio (HR): 0.63 (0.44–0.92); p = 0.016) and OS (HR: 0.60 (0.39–0.93); p = 0.02) between the two biomarker groups when the patients received FOLFIRI (5FUL+irinotecan). Considering only the Microsatellite Stable (MSS) and Microsatellite Instability-Low (MSI-L) patients (n = 470), the differences were even more pronounced. In contrast, no significant differences were observed between the groups when patients received 5FUL alone. This study shows that the combination of ABCG2 and TOP1 gene expression significantly divided the Stage III colon cancer patients into two groups regarding benefit from adjuvant treatment with FOLFIRI but not 5FUL.</p>
    

    
    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            <a href="/publication/#2">
              Journal article
            </a>
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9"><em>Cancers 14</em>(4)</div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"><!--
<div class="alert alert-note">
  <div>
    Click the <em>Cite</em> button above to demo the feature to enable visitors to import publication metadata into their reference management software.
  </div>
</div>
 -->
</div>

    





<div class="article-tags">
  
  <a class="badge badge-light" href="/tag/biomarkers/">biomarkers</a>
  
  <a class="badge badge-light" href="/tag/transcriptomics/">transcriptomics</a>
  
  <a class="badge badge-light" href="/tag/crc/">crc</a>
  
</div>



<div class="share-box">
  <ul class="share">
    
      
      
      
        
      
      
      
      <li>
        <a href="mailto:?subject=An%20explorative%20analysis%20of%20ABCG2/TOP-1%20mRNA%20expression%20as%20a%20biomarker%20test%20for%20FOLFIRI%20treatment%20in%20stage%20III%20colon%20cancer%20patients:%20results%20from%20retrospective%20analyses%20of%20the%20PETACC-3%20trial&amp;body=https://bioinfo-recetox.github.io/publication/2020-cancers/" target="_blank" rel="noopener" class="share-btn-email" aria-label="envelope">
          <i class="fas fa-envelope"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.linkedin.com/shareArticle?url=https://bioinfo-recetox.github.io/publication/2020-cancers/&amp;title=An%20explorative%20analysis%20of%20ABCG2/TOP-1%20mRNA%20expression%20as%20a%20biomarker%20test%20for%20FOLFIRI%20treatment%20in%20stage%20III%20colon%20cancer%20patients:%20results%20from%20retrospective%20analyses%20of%20the%20PETACC-3%20trial" target="_blank" rel="noopener" class="share-btn-linkedin" aria-label="linkedin-in">
          <i class="fab fa-linkedin-in"></i>
        </a>
      </li>
    
  </ul>
</div>











  
  
    




  
    



  
  
  
  
  
  <div class="media author-card content-widget-hr">
    
      
      <a href="/author/eva-budinska/"><img class="avatar mr-3 avatar-circle" src="/author/eva-budinska/avatar_hud8eaee7660ad0c038072b8055bd3a3d5_164745_270x270_fill_q75_lanczos_center.jpg" alt="Eva Budinská"></a>
    

    <div class="media-body">
      <h5 class="card-title"><a href="/author/eva-budinska/">Eva Budinská</a></h5>
      <h6 class="card-subtitle">Head of IB2, Assistant Professor of Bioinformatics</h6>
      <p class="card-text">My research interests include metagenomics, multi-omics bioinformatics and translational oncology.</p>
      <ul class="network-icon" aria-hidden="true">
  
    
    
    
      
    
    
    
    
    
    <li>
      <a href="mailto:eva.budinska@recetox.muni.cz" >
        <i class="fas fa-envelope"></i>
      </a>
    </li>
  
    
    
    
    
    
    
    
      
    
    <li>
      <a href="https://scholar.google.com/citations?user=dX1z5OcAAAAJ&amp;hl=en" target="_blank" rel="noopener">
        <i class="ai ai-google-scholar"></i>
      </a>
    </li>
  
</ul>

    </div>
  </div>


  
    




  
    




  
    



  
  
  
  
  
  <div class="media author-card content-widget-hr">
    
      
      <a href="/author/vlad-popovici/"><img class="avatar mr-3 avatar-circle" src="/author/vlad-popovici/avatar_hu83b78ed1466604b146396f5088cef503_42452_270x270_fill_q75_lanczos_center.jpg" alt="Vlad Popovici"></a>
    

    <div class="media-body">
      <h5 class="card-title"><a href="/author/vlad-popovici/">Vlad Popovici</a></h5>
      <h6 class="card-subtitle">Associate Professor of Computer Science</h6>
      <p class="card-text">My research interests include computational pathology, machine learning and biomarker discovery.</p>
      <ul class="network-icon" aria-hidden="true">
  
    
    
    
      
    
    
    
    
    
    <li>
      <a href="mailto:vlad.popovici@recetox.muni.cz" >
        <i class="fas fa-envelope"></i>
      </a>
    </li>
  
    
    
    
    
    
    
    
      
    
    <li>
      <a href="https://scholar.google.com/citations?user=hLJXAncAAAAJ&amp;hl=en" target="_blank" rel="noopener">
        <i class="ai ai-google-scholar"></i>
      </a>
    </li>
  
    
    
    
      
    
    
    
    
    
      
    
    <li>
      <a href="https://github.com/vladpopovici" target="_blank" rel="noopener">
        <i class="fab fa-github"></i>
      </a>
    </li>
  
</ul>

    </div>
  </div>


  
    




  
















  </div>
</div>
  </div>

  <div class="page-footer">
    
    
    <div class="container">
      <footer class="site-footer">

  












  

  

  

  
  






  
  
  

  
  
    
  
  
    
  

  

  
  <p class="powered-by copyright-license-text">
    © 2023 IB2@RECETOX. This work is licensed under <a href="https://creativecommons.org/licenses/by-nc-nd/4.0" rel="noopener noreferrer" target="_blank">CC BY NC ND 4.0</a>
  </p>
  

  <p class="powered-by footer-license-icons">
    <a href="https://creativecommons.org/licenses/by-nc-nd/4.0" rel="noopener noreferrer" target="_blank" aria-label="Creative Commons">
      <i class="fab fa-creative-commons fa-2x" aria-hidden="true"></i>
      <i class="fab fa-creative-commons-by fa-2x" aria-hidden="true"></i>
      
        <i class="fab fa-creative-commons-nc fa-2x" aria-hidden="true"></i>
      
      
        <i class="fab fa-creative-commons-nd fa-2x" aria-hidden="true"></i>
      
    </a>
  </p>




  <p class="powered-by">
    
    
    
      
      
      
      
      
      
      Published with <a href="https://wowchemy.com/?utm_campaign=poweredby" target="_blank" rel="noopener">Wowchemy</a> — the free, <a href="https://github.com/wowchemy/wowchemy-hugo-themes" target="_blank" rel="noopener">open source</a> website builder that empowers creators.
    
  </p>
</footer>

    </div>
    
  </div>

  


<script src="/js/vendor-bundle.min.d26509351aa0ff874abbee824e982e9b.js"></script>




  

  
  

  






  <script src="https://cdn.jsdelivr.net/npm/leaflet@1.7.1/dist/leaflet.min.js" integrity="" crossorigin="anonymous"></script>








  
  <script id="search-hit-fuse-template" type="text/x-template">
    <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
    </div>
  </script>
  
    <script src="https://cdn.jsdelivr.net/gh/krisk/Fuse@v3.2.1/dist/fuse.min.js" integrity="sha512-o38bmzBGX+hD3JHWUFCDA09btWaqrNmoJ3RXLlrysA7PP01Kgs4UlE4MhelE1v5dJR3+cxlR4qQlotsW7jKsnw==" crossorigin="anonymous"></script>
    <script src="https://cdn.jsdelivr.net/gh/julmot/mark.js@8.11.1/dist/jquery.mark.min.js" integrity="sha512-mhbv5DqBMgrWL+32MmsDOt/OAvqr/cHimk6B8y/bx/xS88MVkYGPiVv2ixKVrkywF2qHplNRUvFsAHUdxZ3Krg==" crossorigin="anonymous"></script>
  












  
  
  
  
  
  
  







<script id="page-data" type="application/json">{"use_headroom":true}</script>



  <script src="/js/wowchemy-headroom.c251366b4128fd5e6b046d4c97a62a51.js" type="module"></script>








  
  


<script src="/en/js/wowchemy.min.54dd6e4d8f2e4b1d098381b57f18dd83.js"></script>



  <script src="/js/wowchemy-map.a26e9d2f7238ba5b868384f1c5bc6477.js" type="module"></script>




  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        
        <pre><code></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>


  <script src="/js/wowchemy-publication.68f8d7090562ca65fc6d3cb3f8f2d2cb.js" type="module"></script>
















</body>
</html>
